Cargando…

Impact of senescence‐associated secretory phenotype and its potential as a therapeutic target for senescence‐associated diseases

“Cellular senescence” is a state in which cells undergo irreversible cell cycle arrest in response to a variety of cellular stresses. Once cells senesce, they are strongly resistant to any mitogens, including oncogenic stimuli. Therefore, cellular senescence has been assumed to be a potent anticance...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Sugiko, Kawamoto, Shimpei, Ohtani, Naoko, Hara, Eiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406532/
https://www.ncbi.nlm.nih.gov/pubmed/28165648
http://dx.doi.org/10.1111/cas.13184
_version_ 1783231973309808640
author Watanabe, Sugiko
Kawamoto, Shimpei
Ohtani, Naoko
Hara, Eiji
author_facet Watanabe, Sugiko
Kawamoto, Shimpei
Ohtani, Naoko
Hara, Eiji
author_sort Watanabe, Sugiko
collection PubMed
description “Cellular senescence” is a state in which cells undergo irreversible cell cycle arrest in response to a variety of cellular stresses. Once cells senesce, they are strongly resistant to any mitogens, including oncogenic stimuli. Therefore, cellular senescence has been assumed to be a potent anticancer mechanism. Although irreversible cell‐cycle arrest is traditionally considered the major characteristic of senescent cells, recent studies have revealed some additional functions. Most noteworthy is the increased secretion of various secretory proteins, such as inflammatory cytokines, chemokines, growth factors, and MMPs, into the surrounding extracellular fluid. These newly recognized senescent phenotypes, termed senescence‐associated secretory phenotypes (SASPs), reportedly contribute to tumor suppression, wound healing, embryonic development, and even tumorigenesis promotion. Thus, SASPs appear to be beneficial or deleterious, depending on the biological context. As senescent cells are known to accumulate during the aging process in vivo, it is quite possible that their accumulation in aged tissues promotes age‐associated functional decline and various diseases, including cancers, at least to some extent. Here, we focus on and discuss the functional and regulatory network of SASPs toward opening up new possibilities for controlling aging and aging‐associated diseases.
format Online
Article
Text
id pubmed-5406532
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54065322017-05-01 Impact of senescence‐associated secretory phenotype and its potential as a therapeutic target for senescence‐associated diseases Watanabe, Sugiko Kawamoto, Shimpei Ohtani, Naoko Hara, Eiji Cancer Sci Review Articles “Cellular senescence” is a state in which cells undergo irreversible cell cycle arrest in response to a variety of cellular stresses. Once cells senesce, they are strongly resistant to any mitogens, including oncogenic stimuli. Therefore, cellular senescence has been assumed to be a potent anticancer mechanism. Although irreversible cell‐cycle arrest is traditionally considered the major characteristic of senescent cells, recent studies have revealed some additional functions. Most noteworthy is the increased secretion of various secretory proteins, such as inflammatory cytokines, chemokines, growth factors, and MMPs, into the surrounding extracellular fluid. These newly recognized senescent phenotypes, termed senescence‐associated secretory phenotypes (SASPs), reportedly contribute to tumor suppression, wound healing, embryonic development, and even tumorigenesis promotion. Thus, SASPs appear to be beneficial or deleterious, depending on the biological context. As senescent cells are known to accumulate during the aging process in vivo, it is quite possible that their accumulation in aged tissues promotes age‐associated functional decline and various diseases, including cancers, at least to some extent. Here, we focus on and discuss the functional and regulatory network of SASPs toward opening up new possibilities for controlling aging and aging‐associated diseases. John Wiley and Sons Inc. 2017-04-18 2017-04 /pmc/articles/PMC5406532/ /pubmed/28165648 http://dx.doi.org/10.1111/cas.13184 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Watanabe, Sugiko
Kawamoto, Shimpei
Ohtani, Naoko
Hara, Eiji
Impact of senescence‐associated secretory phenotype and its potential as a therapeutic target for senescence‐associated diseases
title Impact of senescence‐associated secretory phenotype and its potential as a therapeutic target for senescence‐associated diseases
title_full Impact of senescence‐associated secretory phenotype and its potential as a therapeutic target for senescence‐associated diseases
title_fullStr Impact of senescence‐associated secretory phenotype and its potential as a therapeutic target for senescence‐associated diseases
title_full_unstemmed Impact of senescence‐associated secretory phenotype and its potential as a therapeutic target for senescence‐associated diseases
title_short Impact of senescence‐associated secretory phenotype and its potential as a therapeutic target for senescence‐associated diseases
title_sort impact of senescence‐associated secretory phenotype and its potential as a therapeutic target for senescence‐associated diseases
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406532/
https://www.ncbi.nlm.nih.gov/pubmed/28165648
http://dx.doi.org/10.1111/cas.13184
work_keys_str_mv AT watanabesugiko impactofsenescenceassociatedsecretoryphenotypeanditspotentialasatherapeutictargetforsenescenceassociateddiseases
AT kawamotoshimpei impactofsenescenceassociatedsecretoryphenotypeanditspotentialasatherapeutictargetforsenescenceassociateddiseases
AT ohtaninaoko impactofsenescenceassociatedsecretoryphenotypeanditspotentialasatherapeutictargetforsenescenceassociateddiseases
AT haraeiji impactofsenescenceassociatedsecretoryphenotypeanditspotentialasatherapeutictargetforsenescenceassociateddiseases